About
Cyrano Therapeutics
Dedicated to developing innovative therapeutic solutions for smell loss therapy.
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop a therapy for people struggling with the loss of smell and flavor.
Our mission is to push the boundaries of medical science, bringing hope and healing to patients suffering from anosmia through advanced and effective smell loss therapy & treatments. With a team of world-class researchers and clinicians, Cyrano Therapeutics is at the forefront of smell loss therapy research and development, committed to delivering breakthroughs that matter.
We understand the profound impact that smell loss can have on quality of life. That’s why our dedicated research team is focused on creating therapies that restore this essential sense. By combining cutting-edge technology with compassionate care, we aim to offer patients a pathway to recovery and a renewed sense of smell.
At Cyrano Therapeutics, we believe in the power of science to change lives. Our ongoing commitment to innovation ensures that we remain leaders in the field of smell loss therapy, constantly seeking new ways to enhance patient outcomes and improve overall well-being.
Leadership Team
Rick Geoffrion
Founder, President and CEO
& Board Member
Rick has more than 35 years of management experience in the pharmaceutical and medical device sectors. He has led the foundation of 7 therapeutic companies and remains on the Executive Committee of the Medical Device Innovation Consortium and the External Advisory Committee of the Cleveland Clinic. Rick has personally experienced smell and flavor loss and is fully vested in developing a therapeutic solution.
Gerry Brunk
Managing Director, Lumira Ventures
& Board Member
Gerry Brunk is a cofounder and Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Prior to beginning his investing career in 2002, Mr Brunk founded and served in a variety of management and board capacities at several venture capital-funded healthcare companies. Previously, he was an engagement manager in the healthcare practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston.
Taka Koda
Partner, Remiges Ventures &
Board Member
Taka Koda is Partner at Remiges Ventures, a US-Japan venture capital firm focusing on therapeutics. With over 20 years of business development and venture investment experience, he founded and served in board capacities and management roles for start-up companies as well as providing advisory services for business groups. Previously, he was a member of Mitsui’s Private Equity group for venture investments and fund operations both in the US and Japan.
Jackson Streeter, MD
Limited Partner, DeepWork Capital
& Board Member
Dr. Streeter is currently the Director of UF Innovate Ventures at the University of Florida where he manages a venture fund for the Research Foundation. In addition, he manages life science investments for the Florida Opportunity Fund and DeepWork Capital where he is a limited partner. Dr. Streeter is also the inventor of over twenty patents and author on multiple scientific publications.
John Kollins
Biopharmaceutical Industry CEO
John Kollins has more than 30 years of biopharmaceutical industry experience and most recently served as President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a biopharmaceutical company he cofounded to develop STS101 (dihydroergotamine [DHE] nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraines.
Ron Kuppersmith, MD
Chief Medical Advisor
Former President of the American Academy of Otolaryngology–Head and Neck Surgery. Currently the CEO of ENT Specialty Partners, former Board member of Spirox (acquired by Entellus), former Board advisor of Entellus (acquired by Stryker), and former Board Member of Arrinex (acquired by Stryker).
Michael Lusty, PhD
Senior Advisor, CMC
Michael has 25+ years experience in the development, approval and launch of nasal and inhalation products, including the nasal steroid Nasonex® while working at Schering-Plough, Azmacort® inhaler at Kos Pharmaceuticals/ Abbott and nasal midazolam, Nayzilam® for the treatment of seizure while at Ikano Therapeutics prior to its acquisition and launch by UCB.
